It makes the chemicals that go into products made by other companies — and after two hard years, it has just had its best quarter ever. Deepak Nitrite runs two businesses. Phenolics makes phenol, acetone and isopropyl alcohol, where it is India's largest producer; ₹1,775 crore of revenue in the June 2026 quarter. Advanced Intermediates makes nitration, hydrogenation and specialty products for agrochemicals, pharmaceuticals, paper, textiles and personal care; ₹804 crore. Seven plants across five locations, exports to more than 50 countries, 85% of sales domestic. Is it good at it? The answer changed direction this year. The year to March 2026 was poor — revenue fell 4.8% to ₹7,887 crore and profit fell 21% to ₹551 crore, with return on capital dropping from 16.8% to 11.4%. Then the June quarter delivered ₹2,592 crore of revenue, an EBITDA margin of 21% against 11% a year earlier, and profit up 207%. What sits underneath that is integration rather than luck. Management's own line for it: "we're no longer a nitration company that buys nitric acid, we're now a nitrogen company that nitrates."
On the one that decides a commodity chemicals business — how hard the plants run — it has just started running harder than it ever has. For phenol, the measures are operating rate and feedstock cost, because the product itself is a commodity with a published price. Deepak's phenol capacity has reached roughly 400,000 tonnes and management says it hit that run rate for significant periods of the June quarter, held back only by propylene sourcing and a maintenance shutdown. Asked what had changed to allow debottlenecking past what was previously thought to be the asset's ceiling, the deputy managing director answered: "the only thing that has changed is confidence" — later attributing it to advanced process controls. On the second measure, feedstock, management declines to discuss spreads at all, saying only that Deepak secures propylene and benzene at better than index prices. That is unverifiable from outside. In Advanced Intermediates the measure is how much of the basket is value-added rather than commodity, and there the EBIT margin of 8% against Phenolics' 24% says the mix is still weighted the wrong way.
Not today. The question is about 2028. At March 2026 borrowings were ₹1,638 crore against ₹269 crore of cash and a net worth of ₹5,837 crore — debt-to-equity of 0.28. Borrowings did rise from ₹1,267 crore, but that is a company funding plants, not distress. The chief financial officer put the ratio at 0.27 at the June quarter. What matters more is what has been signed. The propylene and polycarbonate project is a ₹11,500 crore commitment, funded 60:40 debt to equity, and the chief financial officer confirmed the entire debt has been tied up. That is roughly twice the company's current net worth, spending into 2028. Nothing on this page's balance sheet is stretched. But a reader looking at 0.28 and concluding this is a low-debt company is reading a photograph of a company that has already agreed to become something else.
The year shrank. The quarter is the best it has ever had. Year to March 2026: revenue ₹7,887 crore, down 4.8%. Profit ₹551 crore, down 21%. EBITDA margin 12.5% against 13.2%. Return on capital 11.4% against 16.8%. On a three-year view revenue has gone nowhere at all — a compound rate of −0.4% — and profit has compounded at −6.6% over five years. June 2026 quarter: revenue ₹2,592 crore, up 35% and 22% sequentially. EBITDA ₹554 crore, up 159%. Profit ₹345 crore, up 207%. EBITDA margin 21%, against 11% a year earlier and 18% in the March quarter. The gap between those two paragraphs is the whole investment question. Management attributes the quarter to integration benefits from plants commissioned over the past two years, better product mix, and procurement — that is, to things that should persist. Phenol spreads, which management refuses to discuss, are the part that might not.
Backwards for the year, sharply forwards for the quarter. Year to March 2026: revenue ₹7,887 crore against ₹8,282 crore, down 4.8%. Profit ₹551 crore against ₹697 crore, down 21%. Earnings per share of ₹40.36. That is the third disappointing year in a row on the top line: revenue has compounded at −0.4% over three years, against 12.6% over five. June 2026 quarter, both segments: Phenolics revenue ₹1,775 crore, up 36%, with EBIT of ₹418 crore, up 254%. Advanced Intermediates revenue ₹804 crore, up 33%, with EBIT of ₹67 crore, up 89%. Group profit ₹345 crore against ₹112 crore. One quarter does not reverse three years. It does, however, make the next two quarters worth watching more closely than the last twelve months were.
On its own, and it is about to do so on a scale that dwarfs the company. No acquisitions. Gross block rose from ₹2,457 crore to ₹3,270 crore, up 33%, with a further ₹1,828 crore sitting in capital work in progress — more than half the completed asset base again, waiting to be switched on. What has already been built: the ammonia-to-amines chain, nitric acid, and expanded nitration and reduction capacity. Commissioning imminently: MIBK, MIBC and acetophenone in August 2026, with a multipurpose agrochemical intermediates plant and an alkylation plant in the September quarter — both delayed a couple of months by contract labour shortages and a national gas shortage. And then the ₹11,500 crore propylene-to-polycarbonate project, targeted for 2028, which includes a plant being physically dismantled at Stade in Germany and shipped to Dahej. India has never had an integrated polycarbonate plant. Everything here is built rather than bought. The scale is the risk, not the method.
Flat for the year, transformed in the quarter. EBITDA margin for the year to March 2026 was 12.5% against 13.2% — down, but by less than a point, which is the definition of holding rather than slipping. Net margin fell further, 8.4% to 7.0%, because depreciation and interest on new plants arrive before the revenue does. The June 2026 quarter broke the pattern: 21.0% EBITDA margin against 10.0% a year earlier. By segment, Phenolics earned a 24% EBIT margin and Advanced Intermediates 8%. Note which business did it. Phenolics is 68% of quarterly revenue and produced 86% of segment EBIT. This is a phenol quarter with an intermediates business attached, and phenol margins are made of spreads the company does not control.
Not currently, and by design as much as by accident. Return on capital employed was 11.4% for the year to March 2026, down from 16.8%. Return on equity 9.4%. For a company that earned north of 20% in its better years, that is a real deterioration. Part of it is the bad year. Part of it is arithmetic that will get worse before it gets better: capital employed is ₹7,475 crore and ₹1,828 crore of that is capital work in progress — assets sitting in the denominator earning nothing yet. The ₹11,500 crore project extends that condition for years. A company mid-build reports poor returns whether or not the build is a good idea. The number to judge it on arrives in 2028.
Roughly one rupee of cash per rupee of profit, and collections are quick. Operating cash flow over three years came to almost exactly the reported profit — a ratio of 0.99. For the year alone, ₹539 crore of cash flow against ₹551 crore of profit, down from ₹625 crore the year before. That is adequate rather than impressive. Cash arrives as reported, but nothing extra is being squeezed out of working capital. Collections are the strong part: debtor days of 70 and inventory at 40 days, both tight for a business selling commodities into industrial customers. The chief financial officer credited tighter inventory discipline and collections for cash generation in the June quarter.
A founder still in the chair at the top, and both his sons made deputy managing directors on the same day. Dr. Deepak C. Mehta is chairman and managing director — both roles, one person. On 9 May 2026, Maulik Mehta and Meghav Mehta were each appointed deputy managing director. Sanjay Upadhyay is director of finance and group chief financial officer, Girish Satarkar an executive director, and Ajay C. Mehta sits as a non-executive director. The independent bench is substantial: Dileep Choksi, Punit Lalbhai, Arvind Nath Agrawal, Mahesh Chhabria, Vipul Shah and Bhumika Batra. Choksi chairs the audit committee with no family member on it, which is the arrangement that matters most. The auditor is Deloitte Haskins & Sells LLP, in a second five-year term running to the 56th annual general meeting, with no qualification, reservation or adverse remark on FY26. Combining chairman and managing director in one person is the governance weakness here, and a family with three of its members in executive roles is the context. The audit committee's composition is the offsetting fact.
Almost nothing, and what there is has not moved in a year. Contingent liabilities at March 2026 totalled ₹47.86 crore, of which ₹47.33 crore is a corporate guarantee given to group companies and ₹0.53 crore a sales tax and value added tax dispute from 2010-11 to 2014-15 still being contested. Management states it expects no cash outflow on the disputes. There are labour matters where the amount is not ascertainable. Against ₹551 crore of profit, none of this signifies. The sales tax figure is identical to last year's. Deloitte recorded no qualification, reservation or adverse remark, and the subsidiaries' CARO reports carry none either.
Nobody else in India makes phenol at this scale. That is the moat and the exposure in one sentence. Deepak is India's largest producer of phenol, acetone, isopropyl alcohol and sodium nitrite. Before its Dahej plant, India imported most of its phenol. That position is why the June quarter's spreads dropped so directly to the bottom line. It is also the difference from Navin Fluorine, the other specialty chemicals company covered here. Navin sells difficult chemistry to a handful of innovators at 34% margins on ₹1,045 crore a quarter. Deepak sells large volumes of commodities and intermediates at 21% on ₹2,592 crore. Two and a half times the revenue, two-thirds the margin. What makes Deepak different is that it is trying to stop being that company. The whole ₹11,500 crore polycarbonate build is an attempt to convert a commodity position into a value-added one — the first integrated polycarbonate plant in the country.
In phenol, nobody in India. In everything else, everybody. Deepak Phenolics is the only integrated phenol-acetone producer of scale in the country, so its competition is imports — largely from South Korea, Taiwan and the Middle East — rather than a domestic rival. That makes its margin a function of international spreads and freight rather than of anyone's pricing decisions. In Advanced Intermediates the field is crowded: Aarti Industries, Vinati Organics, Atul, Jubilant Ingrevia and a long tail of nitration and hydrogenation specialists compete for the same agrochemical and pharmaceutical customers. Against Navin Fluorine, the other specialty chemicals company covered on this site, the comparison is instructive rather than direct. In the June 2026 quarter Deepak turned over ₹2,592 crore at a 21% EBITDA margin; Navin ₹1,045 crore at 34.2%. Deepak is the larger company by some way and the less profitable one per rupee of sales — commodity scale against specialty chemistry, and the two are priced accordingly at 44 times earnings against 63. Where Deepak is heading — polycarbonate, MIBK, fluorination products — puts it into competition with SRF and Gujarat Fluorochemicals in places it does not currently meet them.
Helping: phenol spreads, and two years of plants finally switching on. Hurting: the fact that nobody, including management, will say how long the spreads last. The June quarter's Phenolics EBIT of ₹418 crore against ₹118 crore a year earlier came, in the company's words, from "favourable product spreads, firm domestic realisations and stable volume offtake". Two of those three are market conditions. Asked directly whether the profitability was sustainable, the deputy managing director declined to comment on spreads at all. Genuinely helping, and durable: the ammonia-to-amines chain, nitric acid capacity and expanded nitration and reduction assets are commissioned and stabilised. They reduce input cost and dependence on bought-in raw materials permanently, whatever phenol does. Renewable energy delivered ₹4.5 crore of savings in the quarter. Hurting: three flat years on the top line before this quarter; an Advanced Intermediates business still earning 8% EBIT margins against Phenolics' 24%; and delays — the alkylation and multipurpose plants slipped a couple of months on contract labour availability and a national gas shortage. And the thing that is neither: ₹11,500 crore committed against a ₹5,837 crore net worth, 60% of it debt, for a product India has never made. If it works, Deepak stops being a spreads business. If it is late, or the polycarbonate cycle turns, the debt arrives regardless.
Boom-and-bust in the near term, structurally growing underneath, and Deepak sits in both halves. Commodity intermediates run on spreads set by global feedstock prices and Chinese capacity. The last three years demonstrated the downside: Deepak's revenue went nowhere and its returns halved. This quarter demonstrated the upside, in one quarter. The structural story is import substitution. India consumes far more of these molecules than it makes, and every plant built domestically replaces a shipment. Phenol was the previous instance of that, and Deepak captured it. Polycarbonate is the company's bet on the next one. Both things are true at once, which is why a page like this needs the quarter and the three-year record side by side.
Cheaper than its only covered peer, on earnings that just changed direction. At ₹1,780.50 on 17 August 2026 the company is worth ₹24,286 crore — 44 times the year to March 2026's earnings, 4.2 times book, 3.1 times sales. Forty-four times a bad year is a different proposition from forty-four times a good one. If the June quarter's run rate holds, the multiple on forward earnings is far lower. If it was a spread quarter, it is not. The market appears to have decided: the stock is 5% off its 52-week high having been 30% below it, on a year in which profit fell a fifth.
Expensive on what it earned, possibly cheap on what it is earning. On 17 August 2026 the share was ₹1,780.50 — 44.1 times earnings of ₹40.36 per share, 4.2 times a book value of ₹428, and 3.1 times sales. Earnings yield 2.3%, dividend yield about 0.4%. The trap is the denominator. Those earnings are the year to March 2026, when profit fell 21%. The June quarter alone earned ₹345 crore; four of those would put the multiple near 18. Nobody should annualise one quarter, but nobody should ignore that the trailing figure is measuring a trough either. Against Navin Fluorine, the other specialty chemicals company covered here, Deepak is markedly cheaper — 44 times against 63 — on a business with lower margins and a much larger construction programme ahead of it.
Domestic funds buying, foreign funds edging out, and retail leaving in numbers. Institutions held 30.01% at 30 June 2026, up 0.71 points over four quarters. Domestic institutions did all the work: 22.62% to 23.76%. Foreign institutions went the other way, 6.68% to 6.25%. Mutual funds hold 11.45%. The striking figure is the shareholder count: 382,905, down from 416,258 a year ago. More than 33,000 individual holders left during a year when the share went nowhere, and the public shareholding fell from 21.42% to 20.65%. So the register is consolidating — fewer, larger, more domestic and more institutional. Foreign ownership at 6.25% is low for a company this size, and notably lower than Navin Fluorine's 23.7%.
The Life Insurance Corporation and four domestic funds. No foreign name clears the bar. Above 1% at 30 June 2026: Life Insurance Corporation of India, Kotak Midcap Fund, Franklin India Small Cap Fund, Nippon India Small Cap Fund and ICICI Prudential Multicap Fund. Two things stand out. Every one of them is Indian — no sovereign fund, no global index tracker, which is the direct contrast with Navin Fluorine's register. And two of the five are explicitly small-cap funds, which for a company worth ₹24,286 crore says something about where domestic managers file it. No individual investor holds above 1%.
Paying a real dividend, issuing nothing, and borrowing a great deal. The dividend for the year to March 2026 was ₹7.50 per share — 375% of face value — a payout of 18.6% of profit and a yield of about 0.4%. Nearly three times Navin Fluorine's payout ratio, from a company earning less. No shares were issued: dilution over the year was zero, and the share count has been 13.64 crore throughout. No buyback. The money is coming from debt instead. Borrowings rose from ₹1,267 crore to ₹1,638 crore during the year, and the financing for the ₹11,500 crore propylene and polycarbonate project has been tied up at a 60:40 debt-to-equity split — meaning roughly ₹6,900 crore of borrowing ahead, against a net worth of ₹5,837 crore. A company paying a fifth of its profit out while committing to a project twice its net worth is making a statement about confidence. Whether it is the right one resolves in 2028.
Loading…